missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human PCSK1N (aa 51-156) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (89%), Rat (89%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-52026 (PA5-52026. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
The protein encoded by this gene functions as an inhibitor of prohormone convertase 1, which regulates the proteolytic cleavage of neuroendocrine peptide precursors. The proprotein is further processed into multiple short peptides. A polymorphism within this gene may be associated with obesity.
Specifications
Specifications
| Accession Number | Q9UHG2 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 27344 |
| Name | Human PCSK1N (aa 51-156) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | AI848336; basic protein IA-4; Big LEN; big PEN LEN; Big PEN-LEN; Big SAAS; BigLEN; bLEN; b-LEN; b-PEN-LEN; b-SAAS; granin-like neuroendocrine peptide; IA-4; KEP; Little LEN; little SAAS; lLEN; l-LEN; l-SAAS; N-proSAAS; Pan3; pancreas protein 3; Pcsk1n; PEN; PEN19; PEN-19; PEN20; PEN-20; proprotein convertase 1 inhibitor; Proprotein convertase subtilisin/kexin type 1 inhibitor; proSAAS; pro-SAAS; protein serine alanine alanine serine; SAAS; SAAS CT(1-49); SAAS CT(25-40); SAASCT; SCG8; SgVIII |
| Common Name | PCSK1N |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction